Cargando…
A VLP vaccine for epidemic Chikungunya virus protects non-human primates against infection
Chikungunya virus (CHIKV) has infected millions of people in Africa, Europe, and Asia1,2 since its re-emergence in Kenya in 2004. The severity of disease and spread of this epidemic virus present a serious public health threat in the absence of vaccines or anti-viral therapies. Here, we describe a n...
Autores principales: | Akahata, Wataru, Yang, Zhi-yong, Andersen, Hanne, Sun, Siyang, Holdaway, Heather A., Kong, Wing-Pui, Lewis, Mark G., Higgs, Stephen, Rossmann, Michael G., Rao, Srinivas, Nabel, Gary J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834826/ https://www.ncbi.nlm.nih.gov/pubmed/20111039 http://dx.doi.org/10.1038/nm.2105 |
Ejemplares similares
-
Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization
por: Sun, Siyang, et al.
Publicado: (2013) -
Comparative Efficacy of Hemagglutinin, Nucleoprotein, and Matrix 2 Protein Gene-Based Vaccination against H5N1 Influenza in Mouse and Ferret
por: Rao, Srinivas S., et al.
Publicado: (2010) -
Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus
por: Pal, Pankaj, et al.
Publicado: (2013) -
A Single Mutation in Chikungunya Virus Affects Vector Specificity and Epidemic Potential
por: Tsetsarkin, Konstantin A, et al.
Publicado: (2007) -
Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus
por: Garg, Himanshu, et al.
Publicado: (2020)